September 2018 saw David recognised as being one of the 100 best, brightest and most powerful advocates for pathology in the global community by the Pathologist magazine. David is leading the NHS Improvement Pathology consolidation programme, seeking to deliver efficient, high quality pathology services across England. One year on Pathology services are embracing this considerable change at a pace not previously seen.
David has a diverse experience of providing and leading pathology services to primary, secondary and tertiary care across all pathology disciplines. Trained at Addenbrookes Hospital qualifying in December 2000, followed by a number of roles including Great Ormond Street Hospital as the Lead Healthcare Scientist for GOSH, covering the entire Healthcare Science workforce, the first person to hold this post and as Director of Operations at Viapath covering Kings College Hospital and Guy’s and St Thomas’ Hospitals one of the UK’s largest networked pathology services.
David is an elected IBMS council member for the London Region. David has also represented the IBMS on NICE diagnostic advisory panels, and various national forums including an observer on the Royal College of Pathologist Council and in the Parliamentary and Science committee
Professor Adrian Newland CBE, Professor of Haematology at Barts and the London NHS Trust
Adrian Newland is a Professor of Haematology at Barts and the London NHS Trust, where he developed the leukaemia and bone marrow transplant unit in the early 1980s. He now has a particular interest in immunohaematology and is studying the molecular basis of autoimmune disease, in particular thrombocytopenia, and piloting the clinical use of novel treatments. He is also Centre Lead for Haematology in the Medical School, Director of Pathology for the Trust and Clinical Director of the North East Thames Cancer Network.
Ciaran Fulton is Head of Diagnostics at LifeArc's Centre for Diagnostic Development (CDD) in Edinburgh. With over 15 years' experience in the molecular diagnostic IVD sector he gained his PhD in Molecular Biology at The Queen's University of Belfast and subsequently completed a number of post-doctoral positions at both Queen's and University College Cork where he was an associate lecturer.
Prior to joining LifeArc, Ciaran spent 10 years at Almac Diagnostics in various roles including managing both the company's Service and CLIA laboratories. He has also worked at the Molecular Biology Group at Randox Laboratories as a research scientist developing markers for use in breast cancer diagnostics.
As Head of Diagnostics, Ciaran has overall responsibility for the delivery of diagnostic development projects including all aspects of product development through to clinical evaluation as well as responsibility for the bioinformatics, quality and project management functions within LifeArc.
Lord Jim O'Neill
Lord O’Neill will become the Chair of Chatham House In July. Jim is the Vice Chair of the Northern Powerhouse Partnership. Lord O’Neill is also Chairing the International Advisory Board for the Productivity Insights Network+ Programme, co-ordinated by Sheffield University. He is a member of the Shelter Social Housing Commission. Since leaving from Government in September 2015, having been Commercial Secretary to the Treasury, Jim moved to the Crossbenches of the House of Lords.
Jim led an independent Review into Antimicrobial Resistance (AMR) for David Cameron from late 2014 to September 2016, and remains focused on this challenge. He has recently published a book, “ Superbugs, An Arms Race Against Bacteria” with two of his Review team colleagues, and was also awarded a Fellowship from the Society for Applied Microbiology for his AMR work.
In 2013/ 2014, Jim chaired the Cities Growth Commission in the UK, which formed the impetus for the government’s policy on devolution as well as the concept of the Northern Powerhouse.
Jim earned BA and MA degrees in economics from Sheffield University in 1978 and a PhD from the University of Surrey in 1982. He has honorary degrees from the Institute of Education, University of London, for his educational philanthropy, from City University for his services to banking and finance, and from Sheffield University in recognition of his contribution to international economics. Jim is an Honorary Fellow of the Faculty of Public Health , a Fellow at the Society for Applied Microbiology,and a Fellow of the Academy of Social Sciences.
Fiona Carragher is the Deputy Chief Scientific Officer for England, supporting the head of profession for the 50,000 healthcare science workforce in the NHS and associated bodies – embracing more than 50 separate scientific specialisms. A Consultant Clinical Biochemist by background, Fiona has a broad portfolio of policy responsibilities, providing professional leadership and expert clinical advice across the health and care system as well as working with senior clinical leaders within both the NHS England and the wider NHS.
Fiona has a strong background in both public health and treatment & care, having led and worked in multi-professional teams for two decades at Guy’s & St Thomas’ Hospital, the Royal Hospital for Sick Children, Edinburgh and Kings College Hospital, London – with a focus on providing high quality, innovative laboratory services. More recently she led a number of specialised laboratories for the diagnosis and monitoring of inherited metabolic disease and was Director of Newborn Screening for the South East Thames Region.
She has led a number of broader healthcare science projects including technology adoption and leadership development, and created a proactive scientific and diagnostics network across London that supports quality improvement and effective commissioning.
Clare joined NIBSC in 1998 as a scientist responsible for screening plasma pools for the presence of HIV, following a 2-year graduate post at Hammersmith Hospital working on an HIV drug response clinical trial.
She now has over 16 years of experience in the field of development of international standards and working reagents.
Her main interests are the development of international standards for use in clinical diagnosis and the improvement of current standards to adapt to new technologies.
Melinda (Dolly) is a ‘Specialist Paramedic - urgent care’ in the South Central Ambulance Service and a Trainee Advanced Clinical Practitioner at Royal Berkshire Hospital. She is a degree paramedic who is currently working towards completing her MSc in Advanced Practice. She has experience in the NHS across a number of environments including the ambulance service, minor injuries, the emergency department and within GP practices. She has an interest in reading and writing academic literature with previous publications in the Journal of Paramedic Practice and now Standby CPD.
It is her aim to add to the evidence base that currently inspires paramedic practice whilst learning from it herself. Dolly has been fortunate enough to benefit from senior clinical mentors throughout her training and career such as lifetime Paramedics, Emergency Care Practitioners (ECP), Advanced Care Practitioners (ACP) and General Practitioners (GP). She hopes that the knowledge that she has benefited from can be transferred into her writing to help others within the Paramedic profession.
Professor Dark studied undergraduate physics and then medicine. Graduating from The Manchester Medical School in 1989, he went on to study clinical academic surgery, emergency medicine and critical care at the Universities of Glasgow and Manchester in the UK, and at the Catholic University of Leuven, Belgium. He was a MRC Clinical Training Fellow, completing a PhD supervised by Professor Rod Little at the MRC Trauma Unit in 2002, where he developed non-invasive technologies to transduce and study dynamic cardio-respiratory responses to tissue injury and haemorrhage.
Appointed by the University of Manchester in 2003, he developed his clinical academic practice in Critical Care Medicine as Honorary NHS Consultant at Salford Royal NHS Foundation Trust. He provides leadership for a programme of work funded by the National Institute of Health Research (NIHR) developing and assessing the diagnostic utility of emerging molecular technologies in the setting of sterile tissue injury and severe infection - focused on matrices in blood and breath. Funded by Innovate UK, he has also led a programme of work developing novel technologies aimed at rapid point-of-care infection/sepsis diagnosis and he has advised NICE at a number of diagnostic technology appraisals.
Professor Dark is Academic Director for Greater Manchester’s Major Trauma Centre Collaborative and is NIHR National Research Lead for Critical Care based at King’s College London.
Doris-Ann Williams has been Chief Executive of BIVDA since October 2001. She has more than 35 years’ experience in the IVD sector. She has held a variety of roles, initially in R&D at Amersham International/Amerlite Diagnostics Ltd and subsequently in commercial roles internationally for Becton Dickinson, ICN and Hitachi Chemical Diagnostics.
Doris-Ann also works closely with other global IVD industry associations and in the UK as part of Life Sciences UK. She was awarded an MBE in January 2011 and was recognised as a Friend of the Royal College of Pathologists in November 2012 and also as Friend of the Association for Clinical Biochemistry in July 2015. She is currently a Vice-President of the Parliamentary & Scientific Committee. She is also an active member of a number of Government and NHS steering groups & boards.
During 2016, Doris-Ann was invited to attend the High-Level meeting on Antimicrobial Resistance at the United Nations General Assembly in New York (September) and was a member of the Precision Medicine delegation to India for the Prime Minister’s visit in November.
NovarumTM Dx Founder and BBI Group Head of Mobile. With a PhD in Chemistry and around 15 years working in the diagnostics arena, Dr Neil Polwart specialises in leading mHealth development, delivering connected health and true point of care technology solutions. Neil Polwart has worked in the field of biosensors, for nearly 20 years, developing and commercialising in-field tests for medical and environmental applications. His technical experience includes physics, chemistry, biotechnology and software, but in recent years, Neil has been increasingly focused on commercialisation. In 2012, Neil led a joint venture - namely, Novarum DX based in Edinburgh, combining BBI’s diagnostics expertise with image-capture software which transforms a smartphone into a mobile diagnostic reader.
In late 2016, BBI Group completed the acquisition of Novarum DX, following successful commercialisation of the technology with a number of key clients. Neil now heads up mobile within BBI Group, driving the ambitions of this global diagnostics business into the mHealth arena.
Alison Dennis is co-head of the life sciences sector group and a noted expert in EU regulatory and compliance matters for medical device and IVD companies.
Michael Wakeman is a pharmacist and healthcare consultant. He has a master’s degree in pharmaceutical analysis as well as nutritional medicine, and clinical oncology. He is currently completing a PhD.
He has extensive experience in natural medicines research and worked alongside Nobel laureate in medicine, Sir James Black-whilst MD at Scotia Pharmaceuticals. Since then he has worked as a consultant to a number of blue chip organisations including Genzyme, the US biotech giant, and a number of UK based, multinational companies in the research and development of their business.
Guy Checketts is the Head of Transformation and Evaluation within the SIP Programme at the Oxford AHSN; Guy has had an extensive career throughout the medical device industry and has developed, launched and managed many new medical devices across multiple segments in the UK, Europe and the US.
Julie Hart is Director of Strategic and Industry Partnerships at the Oxford Academic Health Science Network (AHSN) who trained as a research microbiologist and has been leading commercial teams in the diagnostics and life sciences businesses for over 25 years.